Triamcinolone Injection in the Treatment of Malar Edema
Keywords:
malar edema, aesthetic medicine, filler injection, hyaluronic acidAbstract
Introduction: Tear-through deformities can be a detectable sign of facial aging. Over recent years, minimally invasive procedures such as hyaluronic acid filler injections have been shown to be effective in improving this area. Malar edema is the accumulation of fluid over the malar eminence persisting for 1 month or more. Given its nature, the management remains problematic. The most commonly reported treatment modality is injection with hyaluronidase.
Objectives: To determine the safety and efficacy pf triamcinolone injection in the treatment of malar edema.
Methods: A total of 15 female patients with malar edema, with a mean age of 43.77 years, were treated with triamcinolone injections. The volume injected was chosen by the investigator. Prior to the triamcinolone injection, all patients had been treated with hyaluronidase, which turned out to be ineffective in all cases. Patients were asked to note all adverse effects.
Results: Satisfactory results were achieved after a single treatment session for 14 patients and after two treatments for one patient. Overall, injections with triamcinolone were well tolerated and no adverse reactions were reported.
Conclusions: Injection with triamcinolone appears to be a safe and effective option for the management of malar edema following hyaluronic acid filler injection. Nevertheless, further research with larger patient groups is compulsory.
References
Murthy, R., Roos, J. C. P., & Goldberg, R. A. (2019). Periocular hyaluronic acid fillers. Current Opinion in Ophthalmology, 30(5), 395–400.
Griepentrog GJ, Lucarelli MJ, Burkat CN, Lemke BN, Rose JG. Periorbital edema following hyaluronic acid gel injection: a retrospective review. Am J Cosmetic Surg 2011;28(4):251–254
Pessa JE, Garza JR. The malar septum: the anatomic basis of malar mounds and malar edema. Aesthet Surg J. 1997;17(1):11–17.
Funt D, Pavicic T. Dermal fillers in aesthetics: an overview of adverse events and treatment approaches. Clin Cosmet Investig Dermatol. 2013 Dec 12;6:295-316. doi: 10.2147/CCID.S50546. PMID: 24363560; PMCID: PMC3865975.
Hilton S, Schrumpf H, Buhren BA, Bölke E, Gerber PA. Hyaluronidase injection for the treatment of eyelid edema: a retrospective analysis of 20 patients. Eur J Med Res. 2014 May 28;19(1):30. doi: 10.1186/2047-783X-19-30. PMID: 24886711; PMCID: PMC4063423.,
Iverson, S. M., & Patel, R. M. (2017). Dermal filler-associated malar edema: Treatment of a persistent adverse effect. Orbit, 36(6), 473–475. doi:10.1080/01676830.2017.1337
Zhuang, Z., Li, Y., & Wei, X. (2021). The safety and efficacy of intralesional triamcinolone acetonide for keloids and hypertrophic scars: A systematic review and meta-analysis. Burns : journal of the International Society for Burn Injuries, 47(5), 987–998. https://doi.org/10.1016/j.burns.2021.02.013
Gallagher, T., Taliercio, M., Nia, J. K., Hashim, P. W., & Zeichner, J. A. (2020). Dermatologist Use of Intralesional Triamcinolone in the Treatment of Acne. The Journal of clinical and aesthetic dermatology, 13(12), 41–43.
Garelik, J., Babbush, K., Ghias, M., & Cohen, S. R. (2021). Efficacy of high-dose intralesional triamcinolone for hidradenitis suppurativa. International journal of dermatology, 60(2), 217–221. https://doi.org/10.1111/ijd.15124
Song, Y., & Guo, Y. (2018). Granulomatous Reaction to Intralesional Kenalog (Triamcinolone) Injection in Acne. The American Journal of Dermatopathology, 1. doi:10.1097/dad.00000000000013
Mustak, H., Fiaschetti, D., & Goldberg, R. A. (2017). Filling the periorbital hollows with hyaluronic acid gel: Long-term review of outcomes and complications. Journal of Cosmetic Dermatology, 17(4), 611–616. doi:10.1111/jocd.12452
Funt DK. Avoiding malar edema during midface/cheek augmentation with dermal fillers. J Clin Aesthet Dermatol. 2011 Dec;4(12):32-6. PMID: 22191006; PMCID: PMC3244361.
Singh, K., & Nooreyezdan, S. (2020). Nonvascular Complications of Injectable Fillers-Prevention and Management. Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India, 53(3), 335–343. https://doi.org/10.1055/s-0040-1721872
HOLLANDER A. (1961). Intralesional injections of triamcinolone acetonide; a therapy for dermatoses. Antibiotic medicine & clinical therapy (New York, NY), 8, 78–83.
Nauck M, Karakiulakis G, Perruchoud AP, et al: Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 341:309--15, 1998
Penfold PL, Wen L, Madigan MC, et al: Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin Exp Immunol 121:458--65, 2000
Sosnowski J, Stetter-Neel C, Cole D, et al: Protein kinase Cmediated anti-proliferative glucocorticoid-sphinganine synergism in cultured Pollard III prostate tumor cells. J Urol 158:269--74, 1997
Friedman SJ, Butler DF, Pittelkow MR. Perilesional linear atrophy and hypopigmentation after intralesional corticosteroid therapy: report of two cases and review of the literature. J Am Acad Dermatol. 1988;19:537. doi: 10.1016/S0190-9622(88)70209-1.
Siperstein R, Montes JR, Speranza A. A Retrospective Review of the Safety and Efficacy of Low-dose Triamcinolone Mixed with Hyaluronic Acid Fillers to Reduce Post-injection Infraorbital Swelling. J Clin Aesthet Dermatol. 2022 Apr;15(4):13-19. PMID: 35465031; PMCID: PMC9017664.
Siperstein R. Infraorbital Hyaluronic Acid Filler: Common Aesthetic Side Effects With Treatment and Prevention Options. Aesthet Surg J Open Forum. 2022 Jan 15;4:ojac001. doi: 10.1093/asjof/ojac001. PMID: 35386936; PMCID: PMC8982019.
Published
Issue
Section
License
Copyright (c) 2024 Wioletta Barańska-Rybak, Zuzanna Świerczewska, Agnieszka Lemiec, Lee Walker
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
